Methods of treating obesity using antioxidant inflammation modulators
The present invention relates to methods of treating and/or preventing obesity comprising the administration of antioxidant inflammation modulators described herein, including for example bardoxolone methyl.
1. A method of reducing the weight of a human patient that is overweight, comprising administering to the human patient a pharmaceutical composition, comprising an excipient and a compound of the formula:
wherein administration of the pharmaceutical composition reduces the patient's weight, and wherein the patient does not have diabetes, chronic kidney disease (CKD) or cancer.
2. The method of claim 1 , wherein the compound is administered in a daily dose from 5 mg to 50 mg.
3. The method of claim 2 , wherein the daily dose is about 10 mg.
4. The method of claim 2 , wherein the daily dose is about 20 mg.
5. The method of claim 2 , wherein the daily dose is about 40 mg.
6. The method of claim 1 , wherein at least a portion of the compound is present as an amorphous form having an X-ray diffraction pattern (CuKα) with a halo peak at approximately 13.5°2θ, substantially as shown in FIG. 1C , and a T g from about 120° C. to about 135° C.
7. The method of claim 1 , wherein the excipient is a methacrylic acid-ethyl acrylate copolymer.
8. The method of claim 7 , wherein the compound is administered in a daily dose from 5 mg to 50 mg.
9. The method of claim 8 , wherein the daily dose is about 10 mg.
10. The method of claim 8 , wherein the daily dose is about 20 mg.
11. The method of claim 8 , wherein the daily dose is about 40 mg.
12. The method of claim 7 , wherein the monomer ratio in the methacrylic acid-ethyl acrylate copolymer is about 1:1.
13. The method of any one of claim 1 , wherein the compound and the excipient are formulated as a solid dispersion.
14. The method of claim 13 , wherein the compound is administered in a daily dose from 5 mg to 50 mg.
15. The method of claim 14 , wherein the daily dose is about 10 mg.
16. The method of claim 14 , wherein the daily dose is about 20 mg.
17. The method of claim 14 , wherein the daily dose is about 40 mg.
18. The method of claim 1 , wherein the patient does not have insulin resistance or glucose intolerance.
19. The method of claim 1 , wherein the patient does not have cardiovascular disease.
20. The method of claim 1 , wherein the patient does not have fatty liver disease.
21. The method of claim 1 , wherein the patient does not have metabolic syndrome.
22. The method of claim 1 , wherein the patient does not have autoimmune disease, respiratory disease, neurodegenerative disease, liver disease, or infectious disease.
23. The method of claim 1 , wherein the patient is obese.